Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements

TipRanksJan 11 23:39

Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation

TipRanksJan 11 23:37 · Ratings

Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss

Dow JonesJan 11 05:20

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaJan 11 05:06

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesJan 11 03:36 · Ratings

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

BenzingaJan 11 02:40